FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807978322> ?p ?o ?g. }

• W2807978322 abstract "Background Osteoarthritis (OA) is characterised by structural changes of the joint, of which degradation of articular cartilage is one of the major signs 1 . The main proteoglycan component of the extracellular matrix of articular cartilage is aggrecan. GLPG1972 as a potent and selective inhibitor of ADAMTS-5, a key aggrecan-cleaving enzyme involved in cartilage degradation, is being developed as a potential disease-modifying OA drug (DMOAD). Aggrecan cleavage by ADAMTS-5 results in release of N-terminal ARGS neo-epitope fragments of which serum levels significantly decreased in healthy subjects treated with GLPG1972 during 14 days in a previous study². Objectives To assess safety, tolerability, PK and PD (serum ARGS-aggrecan levels) during and following administration of GLPG1972 in patients with knee and/or hip OA. Methods This was a single centre, randomised, double-blind, placebo-controlled, age and gender stratified, ascending dose Phase Ib study, with three semi-sequential cohorts of 10 patients each, randomised to active drug or placebo in a 4:1 ratio. Doses tested were once daily 100, 200 and 300 mg. Treatment duration was 29 days. Patients had follow-up visits 14 and 21 days after last dosing for additional PD assessments. Methods for PD have been described previously³. Results Thirty patients were included. Of these, 24 patients (M/F rate 8/16, 14 aged 50–64 and 10 aged 65–75) received active medication. All adverse events (AE) were mild and transient. No serious AEs were reported during the study; one female patient in the 300 mg group was discontinued after 15 days of treatment due to drug-related elevated transaminase values which returned to normal 9 days later while her bilirubin levels remained normal. There were no overall trends in lab abnormalities over time or significant changes in vital signs, ECG and Holter parameters. Steady state in plasma exposure was reached after 3 days of dosing. Exposure increased dose-proportionally. Mean serum ARGS levels (SEM) decreased steadily over time in all patients receiving GLPG1972: −40% (2.9),%–46% (4.5) and −53% (2.8) at day 15 compared to baseline in the 100, 200 and 300 mg group respectively. These levels remained stable until last dose on day 29, then consistently returned to pre-dose levels for all groups 14 and 21 days after last dose. Placebo group levels remained unchanged. Conclusions When administered daily for 29 days in patients with knee and/or hip OA, GLPG1972 at oral doses of 100, 200 and 300 mg q.d. was generally well tolerated and safe. Serum ARGS levels, as a marker for target engagement and potential proxy of cartilage degradation, showed a dose-dependent decrease over time up to 53% below baseline in the 300 mg group. These PK-PD findings are consistent with what we observed in a previous study in healthy subjects² and reinforce the rationale for developing GLPG1972 as a DMOAD. References [1] Hunter DJ, et al. Curr. Opin. Rheumatol. 2009;21:110–117. [2] van der Aar E, et al. Arthritis Rheumatol . 2017;69(suppl 10). [3] Larsson, et al. Osteoarthritis Cartilage2014;22(2):242–9. Disclosure of Interest H. Deckx Employee of: Galapagos NV, Belgium, S. Hatch Consultant for: Galapagos NV, Belgium, M. Robberechts Employee of: Galapagos NV, Belgium, S. Dupont Employee of: Galapagos SASU, France, J. Desrivot Employee of: has been employee of Galapagos SASU, France, H. Coleman Paid instructor for: Covance has been contracted by Galapagos NV to conduct the study, S. Larsson: None declared, A. Struglics: None declared, E. van der Aar Employee of: Galapagos NV, Belgium, A. Fiew Employee of: Galapagos NV, Belgium" @default.
• W2807978322 created "2018-06-21" @default.
• W2807978322 creator A5007044951 @default.
• W2807978322 creator A5009530965 @default.
• W2807978322 creator A5020112948 @default.
• W2807978322 creator A5031100965 @default.
• W2807978322 creator A5033106418 @default.
• W2807978322 creator A5044777058 @default.
• W2807978322 creator A5064792387 @default.
• W2807978322 creator A5069032543 @default.
• W2807978322 creator A5072166115 @default.
• W2807978322 creator A5078424632 @default.
• W2807978322 date "2018-06-01" @default.
• W2807978322 modified "2023-10-05" @default.
• W2807978322 title "FRI0539 A safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) study with increasing oral doses of glpg1972 administered daily for 29 days shows a strong biomarker effect in patients with KNEE and/or HIP OA" @default.
• W2807978322 doi "https://doi.org/10.1136/annrheumdis-2018-eular.3101" @default.
• W2807978322 hasPublicationYear "2018" @default.
• W2807978322 type Work @default.
• W2807978322 sameAs 2807978322 @default.
• W2807978322 citedByCount "0" @default.
• W2807978322 crossrefType "proceedings-article" @default.
• W2807978322 hasAuthorship W2807978322A5007044951 @default.
• W2807978322 hasAuthorship W2807978322A5009530965 @default.
• W2807978322 hasAuthorship W2807978322A5020112948 @default.
• W2807978322 hasAuthorship W2807978322A5031100965 @default.
• W2807978322 hasAuthorship W2807978322A5033106418 @default.
• W2807978322 hasAuthorship W2807978322A5044777058 @default.
• W2807978322 hasAuthorship W2807978322A5064792387 @default.
• W2807978322 hasAuthorship W2807978322A5069032543 @default.
• W2807978322 hasAuthorship W2807978322A5072166115 @default.
• W2807978322 hasAuthorship W2807978322A5078424632 @default.
• W2807978322 hasBestOaLocation W28079783221 @default.
• W2807978322 hasConcept C111113717 @default.
• W2807978322 hasConcept C112705442 @default.
• W2807978322 hasConcept C126322002 @default.
• W2807978322 hasConcept C142724271 @default.
• W2807978322 hasConcept C197534660 @default.
• W2807978322 hasConcept C197934379 @default.
• W2807978322 hasConcept C204787440 @default.
• W2807978322 hasConcept C27081682 @default.
• W2807978322 hasConcept C2776164576 @default.
• W2807978322 hasConcept C2777288759 @default.
• W2807978322 hasConcept C2778375690 @default.
• W2807978322 hasConcept C3020332539 @default.
• W2807978322 hasConcept C71924100 @default.
• W2807978322 hasConcept C90924648 @default.
• W2807978322 hasConcept C98274493 @default.
• W2807978322 hasConceptScore W2807978322C111113717 @default.
• W2807978322 hasConceptScore W2807978322C112705442 @default.
• W2807978322 hasConceptScore W2807978322C126322002 @default.
• W2807978322 hasConceptScore W2807978322C142724271 @default.
• W2807978322 hasConceptScore W2807978322C197534660 @default.
• W2807978322 hasConceptScore W2807978322C197934379 @default.
• W2807978322 hasConceptScore W2807978322C204787440 @default.
• W2807978322 hasConceptScore W2807978322C27081682 @default.
• W2807978322 hasConceptScore W2807978322C2776164576 @default.
• W2807978322 hasConceptScore W2807978322C2777288759 @default.
• W2807978322 hasConceptScore W2807978322C2778375690 @default.
• W2807978322 hasConceptScore W2807978322C3020332539 @default.
• W2807978322 hasConceptScore W2807978322C71924100 @default.
• W2807978322 hasConceptScore W2807978322C90924648 @default.
• W2807978322 hasConceptScore W2807978322C98274493 @default.
• W2807978322 hasLocation W28079783221 @default.
• W2807978322 hasOpenAccess W2807978322 @default.
• W2807978322 hasPrimaryLocation W28079783221 @default.
• W2807978322 hasRelatedWork W1901732955 @default.
• W2807978322 hasRelatedWork W1982460827 @default.
• W2807978322 hasRelatedWork W1993538945 @default.
• W2807978322 hasRelatedWork W2072598730 @default.
• W2807978322 hasRelatedWork W2094100409 @default.
• W2807978322 hasRelatedWork W2315532788 @default.
• W2807978322 hasRelatedWork W2322687873 @default.
• W2807978322 hasRelatedWork W2327566659 @default.
• W2807978322 hasRelatedWork W2551210591 @default.
• W2807978322 hasRelatedWork W2555694062 @default.
• W2807978322 hasRelatedWork W2562753811 @default.
• W2807978322 hasRelatedWork W2591756107 @default.
• W2807978322 hasRelatedWork W2592919377 @default.
• W2807978322 hasRelatedWork W2774440400 @default.
• W2807978322 hasRelatedWork W2812342912 @default.
• W2807978322 hasRelatedWork W2909707431 @default.
• W2807978322 hasRelatedWork W2990459172 @default.
• W2807978322 hasRelatedWork W3034230354 @default.
• W2807978322 hasRelatedWork W3091939747 @default.
• W2807978322 hasRelatedWork W3176385349 @default.
• W2807978322 isParatext "false" @default.
• W2807978322 isRetracted "false" @default.
• W2807978322 magId "2807978322" @default.
• W2807978322 workType "article" @default.